These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 25775634)

  • 1. Evaluation of the efficacy and safety of topical imiquimod 5% for plaque-type morphea: a multicenter, prospective, vehicle-controlled trial.
    Dytoc M; Wat H; Cheung-Lee M; Sawyer D; Ackerman T; Fiorillo L
    J Cutan Med Surg; 2015; 19(2):132-9. PubMed ID: 25775634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical imiquimod 5% cream for pediatric plaque morphea: a prospective, multiple-baseline, open-label pilot study.
    Pope E; Doria AS; Theriault M; Mohanta A; Laxer RM
    Dermatology; 2011; 223(4):363-9. PubMed ID: 22327486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses.
    Stockfleth E; Meyer T; Benninghoff B; Salasche S; Papadopoulos L; Ulrich C; Christophers E
    Arch Dermatol; 2002 Nov; 138(11):1498-502. PubMed ID: 12437457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru.
    Miranda-Verástegui C; Llanos-Cuentas A; Arévalo I; Ward BJ; Matlashewski G
    Clin Infect Dis; 2005 May; 40(10):1395-403. PubMed ID: 15844060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies.
    Swanson N; Smith CC; Kaur M; Goldenberg G
    J Drugs Dermatol; 2013 Nov; 12(11):1278-82. PubMed ID: 24196337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of keloid scars post-shave excision with imiquimod 5% cream: A prospective, double-blind, placebo-controlled pilot study.
    Berman B; Harrison-Balestra C; Perez OA; Viera M; Villa A; Zell D; Ramirez C
    J Drugs Dermatol; 2009 May; 8(5):455-8. PubMed ID: 19537368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial.
    Gebauer K; Shumack S; Cowen PS
    Br J Dermatol; 2009 Oct; 161(4):897-903. PubMed ID: 19545297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Swanson N; Smith CC; Kaur M; Goldenberg G
    J Drugs Dermatol; 2014 Feb; 13(2):166-9. PubMed ID: 24509967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First case series on the use of imiquimod for morphoea.
    Dytoc M; Ting PT; Man J; Sawyer D; Fiorillo L
    Br J Dermatol; 2005 Oct; 153(4):815-20. PubMed ID: 16181467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial.
    Brown VL; Atkins CL; Ghali L; Cerio R; Harwood CA; Proby CM
    Arch Dermatol; 2005 Aug; 141(8):985-93. PubMed ID: 16103328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream.
    Shaffelburg M
    J Drugs Dermatol; 2009 Jan; 8(1):35-9. PubMed ID: 19180894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Localized morphea treated with imiquimod 5% and dermoscopic assessment of effectiveness.
    Campione E; Paternò EJ; Diluvio L; Orlandi A; Bianchi L; Chimenti S
    J Dermatolog Treat; 2009; 20(1):10-3. PubMed ID: 18651299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles.
    Hanke CW; Beer KR; Stockfleth E; Wu J; Rosen T; Levy S
    J Am Acad Dermatol; 2010 Apr; 62(4):573-81. PubMed ID: 20133012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials.
    Lebwohl M; Dinehart S; Whiting D; Lee PK; Tawfik N; Jorizzo J; Lee JH; Fox TL
    J Am Acad Dermatol; 2004 May; 50(5):714-21. PubMed ID: 15097955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis.
    Kose O; Koc E; Erbil AH; Caliskan E; Kurumlu Z
    J Dermatolog Treat; 2008; 19(3):159-63. PubMed ID: 18569272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laser-assisted tattoo removal with topical 5% imiquimod cream.
    Ricotti CA; Colaco SM; Shamma HN; Trevino J; Palmer G; Heaphy MR
    Dermatol Surg; 2007 Sep; 33(9):1082-91. PubMed ID: 17760599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe.
    Schulze HJ; Cribier B; Requena L; Reifenberger J; Ferrándiz C; Garcia Diez A; Tebbs V; McRae S
    Br J Dermatol; 2005 May; 152(5):939-47. PubMed ID: 15888150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical calcipotriol ointment in the treatment of morphea.
    Tay YK
    J Dermatolog Treat; 2003 Dec; 14(4):219-21. PubMed ID: 14660267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials.
    Korman N; Moy R; Ling M; Matheson R; Smith S; McKane S; Lee JH
    Arch Dermatol; 2005 Apr; 141(4):467-73. PubMed ID: 15837864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies.
    Geisse J; Caro I; Lindholm J; Golitz L; Stampone P; Owens M
    J Am Acad Dermatol; 2004 May; 50(5):722-33. PubMed ID: 15097956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.